Strategies for Treating RCC in the 2nd Line Setting
Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, discusses strategies for the 2nd line renal cell carcinoma (RCC) patients following I-O. Author: obr Added: 07/02/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 2, 2019 Category: Cancer & Oncology Source Type: podcasts

Perspective on Treating Newly Diagnosed RCC Patients
Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, provides perspective on treating newly diagnosed renal cell carcinoma (RCC) patients. Author: obr Added: 07/02/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 2, 2019 Category: Cancer & Oncology Source Type: podcasts

PDIGREE Trial in Metastatic Untreated RCC
Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, explains the design on the outcomes of the PDIGREE trial in metastatic, untreated renal cell carcinoma. Author: obr Added: 07/02/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 2, 2019 Category: Cancer & Oncology Source Type: podcasts

The Next Steps if an HCC Patient Fails 1st Line Therapy
Daneng Li, MD, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, Liver Program Disease Team Lead, City of Hope offers the next steps if a hepatocellular carcinoma (... Author: obr Added: 06/28/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 28, 2019 Category: Cancer & Oncology Source Type: podcasts

Next Phase of HCC Management and Research
Richard S. Finn, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California explains the next phase of hepatocellular carcinoma (HCC) man... Author: obr Added: 06/27/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 27, 2019 Category: Cancer & Oncology Source Type: podcasts

KEYNOTE-240 in 1st Line HCC Outcome
Richard S. Finn, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California explains the outcomes of hepatocellular carcinoma (HCC) in KE... Author: obr Added: 06/27/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 27, 2019 Category: Cancer & Oncology Source Type: podcasts

The Next Steps for an HCC Patient who Fails 1st Line Therapy
Imane El Dika, MD, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center shares the next step for hepatocellular carcinoma (HCC) patient if the 1st line therapy fails. <br /> Author: obr Added: 06/26/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 26, 2019 Category: Cancer & Oncology Source Type: podcasts

Immuno-oncology in the Management of HCC
Imane El Dika, MD, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center explains the role of immuno-oncology (I-O) in the management of hepatocellular carcinoma (HCC) with the recent... Author: obr Added: 06/26/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 26, 2019 Category: Cancer & Oncology Source Type: podcasts